21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Critical role for TRIM28 and HP1β/γ in the epigenetic control of T cell metabolic reprograming and effector differentiation

      research-article
      a , b , 2 , a , a , a , c , a , a , a , a , a , a , a , d , e , f , g , g , a , d , e , d , e , h , c , c , a , i , j , k , d , e , l , m , n , f , g , c , a , 2
      Proceedings of the National Academy of Sciences of the United States of America
      National Academy of Sciences
      T cells, immunology, epigenetics, autoimmunity, TRIM28

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          CD4 T cells are major regulators of immune responses against both self and pathogens. Understanding pathways that govern CD4 T cell differentiation and regulation are thus key for the discovery of new immunoregulatory drug targets. Here, we have identified an epigenetic pathway that regulates the expression of a set of proteins that determine T cell responsiveness. By silencing enhancers distal to a set of genes known to be involved in regulatory T cell function, the epigenetic modifiers TRIM28 and HP1β/γ regulate T cell receptor signaling. This leads to defective metabolic reprograming and inefficient effector differentiation of naive T cells. This mechanism provides an exciting opportunity to regulate T cell responsivity in both autoimmunity and T cell-based immunodeficiencies.

          Abstract

          Naive CD4 + T lymphocytes differentiate into different effector types, including helper and regulatory cells (Th and Treg, respectively). Heritable gene expression programs that define these effector types are established during differentiation, but little is known about the epigenetic mechanisms that install and maintain these programs. Here, we use mice defective for different components of heterochromatin-dependent gene silencing to investigate the epigenetic control of CD4 + T cell plasticity. We show that, upon T cell receptor (TCR) engagement, naive and regulatory T cells defective for TRIM28 (an epigenetic adaptor for histone binding modules) or for heterochromatin protein 1 β and γ isoforms (HP1β/γ, 2 histone-binding factors involved in gene silencing) fail to effectively signal through the PI3K–AKT–mTOR axis and switch to glycolysis. While differentiation of naive TRIM28 −/− T cells into cytokine-producing effector T cells is impaired, resulting in reduced induction of autoimmune colitis, TRIM28 −/− regulatory T cells also fail to expand in vivo and to suppress autoimmunity effectively. Using a combination of transcriptome and chromatin immunoprecipitation-sequencing (ChIP-seq) analyses for H3K9me3, H3K9Ac, and RNA polymerase II, we show that reduced effector differentiation correlates with impaired transcriptional silencing at distal regulatory regions of a defined set of Treg-associated genes, including, for example, NRP1 or Snai3. We conclude that TRIM28 and HP1β/γ control metabolic reprograming through epigenetic silencing of a defined set of Treg-characteristic genes, thus allowing effective T cell expansion and differentiation into helper and regulatory phenotypes.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain.

          Heterochromatin protein 1 (HP1) is localized at heterochromatin sites where it mediates gene silencing. The chromo domain of HP1 is necessary for both targeting and transcriptional repression. In the fission yeast Schizosaccharomyces pombe, the correct localization of Swi6 (the HP1 equivalent) depends on Clr4, a homologue of the mammalian SUV39H1 histone methylase. Both Clr4 and SUV39H1 methylate specifically lysine 9 of histone H3 (ref. 6). Here we show that HP1 can bind with high affinity to histone H3 methylated at lysine 9 but not at lysine 4. The chromo domain of HP1 is identified as its methyl-lysine-binding domain. A point mutation in the chromo domain, which destroys the gene silencing activity of HP1 in Drosophila, abolishes methyl-lysine-binding activity. Genetic and biochemical analysis in S. pombe shows that the methylase activity of Clr4 is necessary for the correct localization of Swi6 at centromeric heterochromatin and for gene silencing. These results provide a stepwise model for the formation of a transcriptionally silent heterochromatin: SUV39H1 places a 'methyl marker' on histone H3, which is then recognized by HP1 through its chromo domain. This model may also explain the stable inheritance of the heterochromatic state.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

            Regulatory T (Treg) cells safeguard against autoimmunity and immune pathology. Because determinants of the Treg cell fate are not completely understood, we have delineated signaling events that control the de novo expression of Foxp3 in naive peripheral CD4 T cells and in thymocytes. We report that premature termination of TCR signaling and inibition of phosphatidyl inositol 3-kinase (PI3K) p110alpha, p110delta, protein kinase B (Akt), or mammalian target of rapamycin (mTOR) conferred Foxp3 expression and Treg-like gene expression profiles. Conversely, continued TCR signaling and constitutive PI3K/Akt/mTOR activity antagonised Foxp3 induction. At the chromatin level, di- and trimethylation of lysine 4 of histone H3 (H3K4me2 and -3) near the Foxp3 transcription start site (TSS) and within the 5' untranslated region (UTR) preceded active Foxp3 expression and, like Foxp3 inducibility, was lost upon continued TCR stimulation. These data demonstrate that the PI3K/Akt/mTOR signaling network regulates Foxp3 expression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells.

              We have described a murine model of IBD that was induced in C.B-17 scid mice by transfer of the CD45RBhi subpopulation of CD4+ T cells from normal BALB/c mice and could be prevented by cotransfer of the CD45RBlo CD4+ T cell subset. Here we have dissected the mechanism of pathogenesis of IBD in this model and used this information for rational immunotherapy of the disease. CD4+ cells from diseased mice displayed a highly polarized Th1 pattern of cytokine synthesis upon polyclonal stimulation in vitro. The administration of anti-IFN gamma MAb to mice soon after T cell transfer prevented development of colitis for up to 12 weeks. Continual neutralization of TNF with anti-TNF MAbs reduced the incidence of severe disease; however, neutralization of TNF during only the first 3-4 weeks had no effect. Severe colitis was completely abrogated in mice treated systemically with rIL-10, but not with rIL-4.
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc. Natl. Acad. Sci. U.S.A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                17 December 2019
                27 November 2019
                27 November 2019
                : 116
                : 51
                : 25839-25849
                Affiliations
                [1] aInstitut Curie, Université Paris Sciences et Lettres , INSERM U932, 75005 Paris, France;
                [2] bTranslational Science and Experimental Medicine, Research and Early Development, Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals Research and Development, AstraZeneca , Gothenburg, 431 83 Mölndal, Sweden;
                [3] cInstitute de Génétique Moléculaire de Montpellier, University of Montpellier , CNRS, 34094 Montpellier, France;
                [4] dInstitut Gustave Roussy , Plateforme Métabolomique/UMR1138, 94800 Villejuif, France;
                [5] eEquipe Labellisée par la Ligue contre le Cancer, Université de Paris, Sorbonne Université , INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France;
                [6] fFaculté de Médecine, Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal , Montréal, QC H3T 1J4, Canada;
                [7] gAxe de Recherche en Immunobiologie du Cancer, Institut de Recherche en Immunologie et Cancérologie , Montréal, QC H3T 1J4, Canada;
                [8] hCNRS, Centre de Physiopathologie de Toulouse Purpan, Université de Toulouse, Université Paul Sabatier , 31330 Toulouse, France;
                [9] iINSERM U1043, Centre de Physiopathologie de Toulouse Purpan, Université de Toulouse, Université Paul Sabatier , 31330 Toulouse, France;
                [10] jInstitut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université Montpellier , 34298 Montpellier, France;
                [11] kInstitut Régional du Cancer Montpellier, Université Montpellier , 34298 Montpellier, France;
                [12] lPôle de Biologie, Hôpital Européen Georges Pompidou , Assistance Publique–Hôpitaux de Paris, 75015 Paris, France;
                [13] mSuzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences , Suzhou 215123, China;
                [14] nDepartment of Women’s and Children’s Health, Karolinska University Hospital, Karolinska Institute , 17177 Stockholm, Sweden
                Author notes
                2To whom correspondence may be addressed. Email: ulf.gehrmann@ 123456astrazeneca.com or sebastian.amigorena@ 123456curie.fr .

                Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved October 28, 2019 (received for review January 30, 2019)

                Author contributions: U.G., M.B., and S.A. designed research; U.G., M.B., E.Z., C.E., J.-M.C., N.B., T.H., G.S., L.J., S.H.-C., S.D., R.P., A.B.-P., P.J.S., F.A., D.L., A.Z.E.A., and M.M.A. performed research; O.J., F.C., G.K., E.G., and J.-C.A. contributed new reagents/analytic tools; U.G., M.B., E.Z., C.G., C.E., M.Y., J.-M.C., T.H., G.S., S.D., R.P., A.B.-P., P.J.S., V.A., A.Z.E.A., M.M.A., C.H., and O.J. analyzed data; and U.G., M.B., and S.A. wrote the paper.

                1U.G. and M.B. contributed equally to this work.

                3Present address: Translational Science and Experimental Medicine, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, 43183 Mölndal, Sweden.

                4E.Z. and C.G. contributed equally to this work.

                Author information
                http://orcid.org/0000-0001-6942-5355
                http://orcid.org/0000-0003-0686-2608
                http://orcid.org/0000-0003-1168-8165
                http://orcid.org/0000-0003-4117-8182
                http://orcid.org/0000-0001-5815-9768
                Article
                201901639
                10.1073/pnas.1901639116
                6925996
                31776254
                bba2a553-9e26-43bc-b04c-970f5850fd66
                Copyright © 2019 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

                History
                Page count
                Pages: 11
                Categories
                PNAS Plus
                Biological Sciences
                Immunology and Inflammation
                PNAS Plus

                t cells,immunology,epigenetics,autoimmunity,trim28
                t cells, immunology, epigenetics, autoimmunity, trim28

                Comments

                Comment on this article